Abstract
The pharmacological properties of a novel selective 5-hydroxytryptamine1A (5-HT1A) receptor antagonist, NAD-299 [(R)-3-N,N-dicyclobutylamino-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide hydrogen (2R,3R)-tartrate monohydrate] were examined in vitro and in vivo and compared with the reference 5-HT1A receptor antagonist, WAY-100635 [N-(2-(1-(4-(2-methoxyphenyl)piperazin-yl))ethyl)-N-(2-pyridinyl) cyclohexanecarboxamide trihydrochloride]. The new compound had high affinity for 5-HT1A receptors in vitro with a Ki value of 0.6 nM. The only other receptors for which NAD-299 had affinity less than 1 μM werealpha-1 and beta adrenoceptors withKi values of 260 and 340 nM, respectively. Thus, the selectivity of NAD-299 for 5-HT1A receptors was more than 400 times. WAY-100635 had considerably higher affinity than NAD-299 for alpha-1 adrenoceptors (Ki = 45 nM) and dopamine D2 and D3 receptors (Ki = 79 and 67 nM, respectively). Like WAY-100635, NAD-299 competitively blocked 5-HT-induced inhibition of vasoactive intestinal peptide-stimulated cAMP production in GH4ZD10 cells and had no intrinsic activity. Both compounds were therefore 5-HT1A receptor antagonists in vitro and also behaved as such inin vivo experiments. Thus, they competitively antagonized the 8-hydroxy-2-(di-n-propylamino)tetralin-induced 5-HT behavioral effects, hypothermia, corticosterone secretion and inhibition of passive avoidance behavior without causing any actions of their own. The effective dose of NAD-299 varied between 0.03 and 0.35 μmol/kg s.c., depending on the test and the dose of 8-hydroxy-2-(di-n-propylamino)tetralin.
Footnotes
-
Send reprint requests to: Dr Svante B. Ross, Behavioural and Biochemical Pharmacology, Preclinical R & D, Astra Arcus AB, S-151 85 Södertälje, Sweden.
- Abbreviations:
- DA
- dopamine
- DOPA
- l-3,4-dihydroxyphenylalanine
- 8-OH-DPAT
- 8-hydroxy-2-(di-n-propylamino)tetralin
- 5-HT
- 5-hydroxytryptamine
- IBMX
- 3-isobutyl-1-methylxanthine
- 5-HTP
- 5-hydroxytryptophan
- NAD-299
- (R)-3-N,N-dicyclobutylamino-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide hydrogen (2R,3R)-tartrate monohydrate
- NSD 1015
- 3-hydroxybenzylhydrazine dihydrochloride
- (S)-UH-301
- (S)-5-fluoro-8-hydroxy-2-(dipropylamino)tetralin
- VIP
- vasoactive intestinal peptide
- WAY-100135
- N-tert-butyl-3-(4-(2-methoxyphenyl)piperacine-1-yl)-2-phenylpropanamide dihydrochloride
- WAY-100635
- N-(2-(1-(4-(2-methoxyphenyl)piperazinyl))ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide trihydrochloride
- CHO
- Chinese hamster ovary
- FCS
- fetal calf serum
- HEPES
- N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid
- EDTA
- ethylenediaminetetraacetic acid
- ANOVA
- analysis of variance
- AMPA
- dl-α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid
- DHA
- dihydroalprenolol
- GABA
- γ-aminobutyric acid
- NMDA
- N-methyl-d-aspartate
- TBPS
- tert-butylbicyclophosphothionate
- QNB
- l-quinuclidinyl benzilate
- Received December 31, 1996.
- Accepted June 9, 1997.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|